--New Proteomics Data Further Confirms the
Relationship between CM-101's CCL24 Target and
Primary Sclerosing Cholangitis (PSC) Disease
Pathways--
--Provides Further Evidence that CM-101
Interrupts Fibrotic and Inflammatory Disease Processes Driven by
Elevated Levels of CCL24--
TEL
AVIV, Israel and VIENNA, June 26,
2023 /PRNewswire/ -- Chemomab Therapeutics Ltd.
(Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company
developing innovative therapeutics to treat rare fibro-inflammatory
diseases with high unmet need, today reported that it presented two
scientific posters supporting the clinical rationale for the
company's primary sclerosing cholangitis (PSC) program at EASL
2023, the Annual Congress of the European Association for the Study
of the Liver, which took place June 21-24,
2023 in Vienna,
Austria.
"The preclinical data presented at EASL further augments the
comprehensive and consistent body of evidence implicating CCL24 as
a driver of disease pathology in PSC. The data also highlights the
ability of CM-101, our first-in-class CCL24-neutralizing antibody,
to interrupt the fibro-inflammatory vicious cycle that underlies
PSC and other fibrotic diseases," noted Adi
Mor, PhD, co-founder, Chief Executive Officer and Chief
Scientific Officer of Chemomab. "These data, along with the
positive Phase 2a liver fibrosis biomarker data we reported in a
late-breaking EASL poster last week, add to our enthusiasm for our
global Phase 2 PSC trial assessing CM-101 as a potential therapy
for this serious disease that lacks effective treatments."
One of the posters reports on a new proteomic study
demonstrating a direct relationship between the pro-inflammatory,
pro-fibrotic signaling protein CCL24 and PSC disease-related
pathways.1 CCL24 is overexpressed in the livers of PSC
patients, especially in areas of biliary injury. By analyzing
proteomic data from PSC patients and healthy controls, the study
confirms that CCL24 plays a significant role in PSC and its
associated pathways. It found that patients with high CCL24 levels
had upregulated pathways related to PSC and disease severity. CCL24
levels were also significantly correlated with serum proteins
associated with inflammation, fibrosis and vascularization.
Additionally, in a new in vitro study, CCL24-stimulated hepatic
fibroblasts exhibited elevated proteins similar to those seen in
patients with severe PSC. These proteins can serve as a signature
distinguishing PSC patients from healthy controls and
differentiating them by the severity of their condition. Notably,
in this study treatment with CM-101 blocked these CCL24-induced
changes in signature protein expression.
Another poster presented at the EASL conference described the
clinical design and endpoints for Chemomab's ongoing double-blind,
placebo-controlled, multiple dose Phase 2a trial of CM-101 in PSC
patients. Topline results from this trial are anticipated in the
latter half of 2024.
"These posters, which add to the preclinical evidence supporting
CM-101's potential as an effective therapy for PSC, are encouraging
as we look forward to the results from this proof-of-concept
clinical trial," noted Massimo
Pinzani, MD, a co-author of the two posters, co-investigator
of the Phase 2a PSC clinical trial and a clinical hepatologist and
Professor of Medicine and Director of the UCL Institute for Liver
and Digestive Health and the Shelia Sherlock Chair of Hepatology at
University College London. "Results from this trial are intended to
further elucidate the role of CCL24 in inflammatory and fibrotic
disease, to provide an early demonstration of the therapeutic
potential of CM-101 in this poorly-treated condition, and to help
inform future clinical studies. As expected, a recent, planned
interim meeting of the Data Monitoring Committee found no safety
concerns and the clinical team is pressing ahead towards a topline
data readout later next year."
The posters will be available on the Chemomab website starting
this week at www.chemomab.com/r-d/.
- Serum proteomics reveals association of CCL24 with key
aspects of primary sclerosing cholangitis, Raanan Greenman, Tom
Snir, Omer Levi, Avi Katav, John
Lawler, Douglas Thorburn,
Massimo Pinzani, Ilan Vaknin, Revital
Aricha, June 23, 2023,
Immune-mediated and cholestatic: Experimental and pathophysiology
session, EASL abstract #2178
- Targeting CCL24 in primary sclerosing cholangitis with
CM-101: rationale and study design, Douglas Thorburn,
Massimo Pinzani, Palak Trivedi, Christopher Bowlus, Rifaat Safadi, Christina
Crater, John Lawler,
Adi Mor, Chris Cirillo, Matthew Frankel, June 22,
2023, Rare liver diseases session, EASL abstract
#303
About Chemomab Therapeutics
Chemomab is a clinical
stage biotechnology company discovering and developing innovative
therapeutics for fibro-inflammatory diseases with high unmet need.
Based on the unique and pivotal role of the signaling protein CCL24
in promoting fibrosis and inflammation, Chemomab developed CM-101,
a monoclonal antibody designed to neutralize CCL24 activity. In
preclinical and clinical studies, CM-101 appears safe, with the
potential to treat multiple severe and life-threatening
fibro-inflammatory diseases. Chemomab has reported encouraging
results from three clinical trials of CM-101, including a Phase 2
liver fibrosis trial in NASH patients and an investigator-initiated
study in patients with severe lung injury. A Phase 2 trial in
primary sclerosing cholangitis patients is ongoing, with topline
data expected in the latter part of 2024. For more information
about Chemomab, visit chemomab.com.
Forward Looking Statements
This press release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act. These forward-looking statements
include, among other things, statements regarding the clinical
development pathway for CM-101; the future operations of Chemomab
and its ability to successfully initiate and complete clinical
trials and achieve regulatory milestones; the nature, strategy and
focus of Chemomab; the development and commercial potential and
potential benefits of any product candidates of Chemomab; and that
the product candidates have the potential to address high unmet
needs of patients with serious fibrosis-related diseases and
conditions. Any statements contained in this communication that are
not statements of historical fact may be deemed to be
forward-looking statements. These forward-looking statements are
based upon Chemomab's current expectations. Forward-looking
statements involve risks and uncertainties. Because such statements
deal with future events and are based on Chemomab's current
expectations, they are subject to various risks and uncertainties
and actual results, performance or achievements of Chemomab could
differ materially from those described in or implied by the
statements in this presentation, including those found under the
caption "Risk Factors" and elsewhere in Chemomab's filings and
reports with the SEC. Chemomab expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Chemomab's expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based, except as required by law.
Contacts:
|
|
Investors:
|
Investors &
Media:
|
Irina Koffler
|
Barbara
Lindheim
|
LifeSci Advisors,
LLC
|
Chemomab
Therapeutics
|
Phone: +1 (917)
734-7387
|
Consulting Vice
President, Investor & Public Relations
|
ir@chemomab.com
|
Strategic
Communications
|
|
barbara.lindheim@chemomab.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-presents-data-reinforcing-the-clinical-potential-of-cm-101-as-a-novel-treatment-for-primary-sclerosing-cholangitis-at-easl-2023-301862769.html
SOURCE Chemomab Therapeutics, Ltd.